ASX Mkt. Sensitive<p>Orthocell ( <a href="https://mastodon-grafa.social/tags/OCC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OCC</span></a> ) has released " Remplir Approved to Commence Sales in the Hong Kong Market " on Mon 12 May at 08:56 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <br><a href="https://grafa.com/asset/orthocell-ltd-177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/orthocell-ltd-</span><span class="invisible">177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx</span></a></p>
Recent searches
No recent searches
Search options
Only available when logged in.
toad.social is one of the many independent Mastodon servers you can use to participate in the fediverse.
Mastodon server operated by David Troy, a tech pioneer and investigative journalist addressing threats to democracy. Thoughtful participation and discussion welcome.
Administered by:
Server stats:
320active users
toad.social: About · Profiles directory · Privacy policy
Mastodon: About · Get the app · Keyboard shortcuts · View source code · v4.3.8
#clinicaltrials
6 posts · 5 participants · 0 posts today
ASX Mkt. Sensitive<p>Radiopharm Theranostics ( <a href="https://mastodon-grafa.social/tags/RAD" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>RAD</span></a> ) has released " Acceleration of RAD204 Phase 1 dose escalation trial " on Mon 12 May at 08:46 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <br><a href="https://grafa.com/asset/radiopharm-theranostics-ltd-9570-rad.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=rad.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/radiopharm-the</span><span class="invisible">ranostics-ltd-9570-rad.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=rad.asx</span></a></p>
ASX Mkt. Sensitive<p>Orthocell ( <a href="https://mastodon-grafa.social/tags/OCC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OCC</span></a> ) has released " 12 Distributors Signed for Remplir Covering 21 States in US " on Fri 09 May at 08:58 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <br><a href="https://grafa.com/asset/orthocell-ltd-177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/orthocell-ltd-</span><span class="invisible">177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx</span></a></p>
Bytes Europe<p>After Near Miss, What’s Next for Women’s Health Initiative? <a href="https://www.byteseu.com/992906/" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="">byteseu.com/992906/</span><span class="invisible"></span></a> <a href="https://pubeurope.com/tags/BreastCancer" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BreastCancer</span></a> <a href="https://pubeurope.com/tags/BreastCarcinoma" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BreastCarcinoma</span></a> <a href="https://pubeurope.com/tags/Cancer" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Cancer</span></a> <a href="https://pubeurope.com/tags/carcinoma" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>carcinoma</span></a> <a href="https://pubeurope.com/tags/CardiovascularRisk" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>CardiovascularRisk</span></a> <a href="https://pubeurope.com/tags/CardiovascularRiskFactors" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>CardiovascularRiskFactors</span></a> <a href="https://pubeurope.com/tags/CardiovascularRiskManagement" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>CardiovascularRiskManagement</span></a> <a href="https://pubeurope.com/tags/ClinicalResearch" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalResearch</span></a> <a href="https://pubeurope.com/tags/ClinicalStudies" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalStudies</span></a> <a href="https://pubeurope.com/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://pubeurope.com/tags/CVRisk" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>CVRisk</span></a> <a href="https://pubeurope.com/tags/CVRiskFactors" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>CVRiskFactors</span></a> <a href="https://pubeurope.com/tags/Health" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Health</span></a> <a href="https://pubeurope.com/tags/Heart" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Heart</span></a> <a href="https://pubeurope.com/tags/HormonalTherapy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>HormonalTherapy</span></a> <a href="https://pubeurope.com/tags/HormoneTherapy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>HormoneTherapy</span></a> <a href="https://pubeurope.com/tags/MalignantBreastNeoplasm" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MalignantBreastNeoplasm</span></a> <a href="https://pubeurope.com/tags/MalignantNeoplasia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MalignantNeoplasia</span></a> <a href="https://pubeurope.com/tags/MalignantNeoplasm" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MalignantNeoplasm</span></a> <a href="https://pubeurope.com/tags/MenopausalSyndrome" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MenopausalSyndrome</span></a> <a href="https://pubeurope.com/tags/menopause" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>menopause</span></a> <a href="https://pubeurope.com/tags/poisoning" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>poisoning</span></a> <a href="https://pubeurope.com/tags/toxicity" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>toxicity</span></a> <a href="https://pubeurope.com/tags/toxicology" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>toxicology</span></a> <a href="https://pubeurope.com/tags/toxins" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>toxins</span></a></p>
ASX Mkt. Sensitive<p>Nyrada ( <a href="https://mastodon-grafa.social/tags/NYR" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NYR</span></a> ) has released " NYR-BI03 Extends Cardioprotection to Arrhythmia Control " on Thu 08 May at 08:56 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/nyrada-inc-3430-nyr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=nyr.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/nyrada-inc-343</span><span class="invisible">0-nyr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=nyr.asx</span></a></p>
Igor D. Bandeira :verified:<p>Our study explores innovative strategies to prolong the antisuicidal effects of ketamine in individuals with treatment-resistant depression, a critical step toward improving outcomes for patients in crisis.</p><p>This recognition not only supports early-career researchers like myself, but also strengthens our collective mission to advance evidence-based care for depression and suicidality.</p><p><a href="https://med-mastodon.com/tags/ADAA2025" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ADAA2025</span></a> <a href="https://med-mastodon.com/tags/SuicidePrevention" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>SuicidePrevention</span></a> <a href="https://med-mastodon.com/tags/DepressionResearch" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>DepressionResearch</span></a> <a href="https://med-mastodon.com/tags/CareerDevelopment" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>CareerDevelopment</span></a> <a href="https://med-mastodon.com/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://med-mastodon.com/tags/MentalHealthResearch" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MentalHealthResearch</span></a></p>
Flipboard Culture Desk<p>Can you treat grief with a pill? Naltrexone, which is used to treat alcohol and opioid addictions, has been mooted as a way to help people with prolonged grief disorder (the premise being that they have become "addicted" to the person they lost). Ayesha Habib, whose father died when she was 21, writes for The Walrus about the many issues with this approach. "After my dad’s passing, my friends at the time grew awkward around me. They didn’t know how to speak to me, and some disappeared from my life entirely. Every person has a different way of understanding death and grief," she writes. </p><p>“In a world where grief literacy is so low, I worry about our intolerance for being present with people in pain,” says Marney Thompson, the director of the bereavement services program at Victoria Hospice in British Columbia. “I think we’re so quick to jump to the solution, the fix, the ‘get over it’ that we just don’t allow space for real human emotion, which is sadness and sorrow and suffering.”</p><p><a href="https://flip.it/zOGH7d" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="">flip.it/zOGH7d</span><span class="invisible"></span></a></p><p><a href="https://flipboard.social/tags/Grief" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Grief</span></a> <a href="https://flipboard.social/tags/Bereavement" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Bereavement</span></a> <a href="https://flipboard.social/tags/Psychology" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Psychology</span></a> <a href="https://flipboard.social/tags/Psychiatry" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Psychiatry</span></a> <a href="https://flipboard.social/tags/Science" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Science</span></a> <a href="https://flipboard.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a></p>
US News in English<p>Alterity Therapeutics receives FDA fast track designation for ATH434 in mul... - published 05 May 2025 <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <a href="https://mastodon-grafa.social/tags/BioTech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BioTech</span></a> <a href="https://mastodon-grafa.social/tags/Technology" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Technology</span></a> <br><a href="https://grafa.com/news/health-alterity-therapeutics-receives-fda-fast-track-designation-for-ath434-in-multiple-system-atrophy-426683?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=426683" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-alterity</span><span class="invisible">-therapeutics-receives-fda-fast-track-designation-for-ath434-in-multiple-system-atrophy-426683?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=426683</span></a></p>
UK<p><a href="https://www.europesays.com/uk/70983/" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="">europesays.com/uk/70983/</span><span class="invisible"></span></a> Genetic medicine can leave people with rare mutations behind. But there’s new hope #121199049 <a href="https://pubeurope.com/tags/article" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>article</span></a> <a href="https://pubeurope.com/tags/BirthDefects" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BirthDefects</span></a> <a href="https://pubeurope.com/tags/Business" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Business</span></a> <a href="https://pubeurope.com/tags/Cancer" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Cancer</span></a> <a href="https://pubeurope.com/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://pubeurope.com/tags/CysticFibrosis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>CysticFibrosis</span></a> <a href="https://pubeurope.com/tags/GeneTherapy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>GeneTherapy</span></a> <a href="https://pubeurope.com/tags/Genetics" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Genetics</span></a> <a href="https://pubeurope.com/tags/Health" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Health</span></a> <a href="https://pubeurope.com/tags/Medication" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Medication</span></a> <a href="https://pubeurope.com/tags/philanthropy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>philanthropy</span></a> <a href="https://pubeurope.com/tags/Science" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Science</span></a> <a href="https://pubeurope.com/tags/UK" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UK</span></a> <a href="https://pubeurope.com/tags/UnitedKingdom" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedKingdom</span></a></p>
ASX Mkt. Sensitive<p>Nyrada ( <a href="https://mastodon-grafa.social/tags/NYR" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NYR</span></a> ) has released " Phase I Clinical Trial Dosing Update No 2 " on Fri 02 May at 08:48 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/nyrada-inc-3430-nyr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=nyr.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/nyrada-inc-343</span><span class="invisible">0-nyr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=nyr.asx</span></a></p>
Benjamin Carr, Ph.D. 👨🏻💻🧬<p><a href="https://hachyderm.io/tags/Kennedy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Kennedy</span></a> Issues Demands for <a href="https://hachyderm.io/tags/Vaccine" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Vaccine</span></a> Approvals That Could Affect Fall <a href="https://hachyderm.io/tags/CovidBoosters" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>CovidBoosters</span></a><br>Health Secretary <a href="https://hachyderm.io/tags/RFK" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>RFK</span></a> Jr. announced a plan that would require placebo-controlled studies for all new vaccines, surprising some experts who noted that such testing already routinely takes place. <br>The agency suggested that <a href="https://hachyderm.io/tags/clinicaltrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>clinicaltrials</span></a> in humans may be required for updated <a href="https://hachyderm.io/tags/Covid" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Covid</span></a> shots, raising questions about whether they will be available in the fall.<br><a href="https://www.nytimes.com/2025/05/01/us/rfk-jr-vaccine-safety-placebos-covid.html" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="ellipsis">nytimes.com/2025/05/01/us/rfk-</span><span class="invisible">jr-vaccine-safety-placebos-covid.html</span></a><br><a href="https://archive.ph/ffr54" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="">archive.ph/ffr54</span><span class="invisible"></span></a></p>
ASX Mkt. Sensitive<p>Orthocell ( <a href="https://mastodon-grafa.social/tags/OCC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OCC</span></a> ) has released " Remplir Approved to Commence Sales in US$75m Canadian Market " on Wed 30 Apr at 09:08 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <br><a href="https://grafa.com/asset/orthocell-ltd-177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/orthocell-ltd-</span><span class="invisible">177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx</span></a></p>
ASX Mkt. Sensitive<p>Actinogen Medical ( <a href="https://mastodon-grafa.social/tags/ACW" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ACW</span></a> ) has released " Actinogen March 2025 quarterly activity report & Appendix 4C " on Wed 30 Apr at 09:05 AEST <a href="https://mastodon-grafa.social/tags/tax" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>tax</span></a> <a href="https://mastodon-grafa.social/tags/government" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>government</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <br><a href="https://grafa.com/asset/actinogen-medical-ltd-5264-acw.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=acw.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/actinogen-medi</span><span class="invisible">cal-ltd-5264-acw.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=acw.asx</span></a></p>
ASX Mkt. Sensitive<p>Syntara ( <a href="https://mastodon-grafa.social/tags/SNT" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>SNT</span></a> ) has released " Quarterly Activities Report " on Wed 30 Apr at 09:03 AEST <a href="https://mastodon-grafa.social/tags/tax" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>tax</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/pharmaxis-ltd-3819-snt.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=snt.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/pharmaxis-ltd-</span><span class="invisible">3819-snt.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=snt.asx</span></a></p>
ASX Mkt. Sensitive<p>Noxopharm ( <a href="https://mastodon-grafa.social/tags/NOX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NOX</span></a> ) has released " March 2025 Quarterly Activities Report and Appendix 4C " on Wed 30 Apr at 08:55 AEST <a href="https://mastodon-grafa.social/tags/tax" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>tax</span></a> <a href="https://mastodon-grafa.social/tags/government" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>government</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/News" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>News</span></a> <br><a href="https://grafa.com/asset/noxopharm-ltd-8713-nox.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=nox.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/noxopharm-ltd-</span><span class="invisible">8713-nox.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=nox.asx</span></a></p>
ASX Mkt. Sensitive<p>Island Pharmaceuticals ( <a href="https://mastodon-grafa.social/tags/ILA" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ILA</span></a> ) has released " Quarterly Activities & Cashflow Report " on Wed 30 Apr at 08:31 AEST <a href="https://mastodon-grafa.social/tags/tax" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>tax</span></a> <a href="https://mastodon-grafa.social/tags/government" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>government</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/News" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>News</span></a> <br><a href="https://grafa.com/asset/island-pharmaceuticals-ltd-7742-ila.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=ila.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/island-pharmac</span><span class="invisible">euticals-ltd-7742-ila.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=ila.asx</span></a></p>
ASX Mkt. Sensitive<p>Orthocell ( <a href="https://mastodon-grafa.social/tags/OCC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OCC</span></a> ) has released " Replacement Trading Halt " on Tue 29 Apr at 11:52 AEST <a href="https://mastodon-grafa.social/tags/trading" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>trading</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <br><a href="https://grafa.com/asset/orthocell-ltd-177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/orthocell-ltd-</span><span class="invisible">177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx</span></a></p>
ASX Mkt. Sensitive<p>Orthocell ( <a href="https://mastodon-grafa.social/tags/OCC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OCC</span></a> ) has released " Trading Halt " on Tue 29 Apr at 11:23 AEST <a href="https://mastodon-grafa.social/tags/trading" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>trading</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <br><a href="https://grafa.com/asset/orthocell-ltd-177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/orthocell-ltd-</span><span class="invisible">177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx</span></a></p>
ASX Mkt. Sensitive<p>IDT Australia ( <a href="https://mastodon-grafa.social/tags/IDT" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>IDT</span></a> ) has released " Quarterly Revenue Growth of 30% with $62M in Open Proposals " on Tue 29 Apr at 10:04 AEST <a href="https://mastodon-grafa.social/tags/tax" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>tax</span></a> <a href="https://mastodon-grafa.social/tags/UnitedStates" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStates</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <br><a href="https://grafa.com/asset/idt-australia-ltd-7707-idt.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=idt.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/idt-australia-</span><span class="invisible">ltd-7707-idt.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=idt.asx</span></a></p>
UK<p><a href="https://www.europesays.com/uk/52461/" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="">europesays.com/uk/52461/</span><span class="invisible"></span></a> Genetic medicine can leave people with rare mutations behind. But there’s new hope <a href="https://pubeurope.com/tags/APTopNews" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>APTopNews</span></a> <a href="https://pubeurope.com/tags/BirthDefects" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BirthDefects</span></a> <a href="https://pubeurope.com/tags/Business" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Business</span></a> <a href="https://pubeurope.com/tags/Cancer" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Cancer</span></a> <a href="https://pubeurope.com/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://pubeurope.com/tags/CysticFibrosis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>CysticFibrosis</span></a> <a href="https://pubeurope.com/tags/GarryCutting" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>GarryCutting</span></a> <a href="https://pubeurope.com/tags/GeneTherapy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>GeneTherapy</span></a> <a href="https://pubeurope.com/tags/Genetics" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Genetics</span></a> <a href="https://pubeurope.com/tags/Health" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Health</span></a> <a href="https://pubeurope.com/tags/Medication" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Medication</span></a> <a href="https://pubeurope.com/tags/PAStateWire" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>PAStateWire</span></a> <a href="https://pubeurope.com/tags/philanthropy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>philanthropy</span></a> <a href="https://pubeurope.com/tags/Science" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Science</span></a> <a href="https://pubeurope.com/tags/UK" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UK</span></a> <a href="https://pubeurope.com/tags/UnitedKingdom" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedKingdom</span></a></p>
ExploreLive feeds
Mastodon is the best way to keep up with what's happening.
Follow anyone across the fediverse and see it all in chronological order. No algorithms, ads, or clickbait in sight.
Create accountLoginDrag & drop to upload